🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital55 Merck Sharp & Dohme LLC36 Anhui Medical University29 AstraZeneca27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.25
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hefei

875 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
NCT07121777Autoimmune Diseases
Anhui Provincial Hospital
Not applicable
18
Hefei
2025-08-25
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650Diffuse Large B-Cell Lymphoma
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Active, closed
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
NCT07246889Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 3
577
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-12
Recruiting
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT07239947Atopic Dermatitis
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Recruiting
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease
NCT07031531Premature Coronary Heart Disease
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
NCT07029451Infertility
Ferring Pharmaceuticals
Observational
2,500
Hefei, Ma’anshan, Beijing, Chaoyang, Xicheng, Guangzhou, Shantou, Nanning
2025-08-05
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
NCT06871228Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Recruiting
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07093411B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
Beijing GoBroad Hospital
Phase EARLY_PHASE1
48
Hefei, Xi'an, Xuzhou
2025-08-05
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Hefei, Fuzhou, Guangzhou, Baoding, Wuhan, Changsha, Nanjing, Dalian
2025-08-05
Recruiting
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Hefei
2025-08-04
Recruiting
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Phase 1
40
Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai
2025-08-04
By invitation
Study on the Mechanism of Zuoqing San Promoting Postoperative Wound Healing of Anal Fistula by Inhibiting ROS-dependent NETosis
NCT07128953Anal Fistula
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Phase EARLY_PHASE1
60
Hefei
2025-08-01
Not yet open
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
NCT07100236Primary Hepatocellular Carcinoma
Junjie Xu
Observational
350
Hefei, Chaoyang, Fuzhou, Guangzhou, Zhengzhou, Shanghai, Hangzhou, Wenzhou
2025-08-01
Recruiting
EVT in Acute Basilar Artery Occlusion With Large Infarction Core
NCT07090941Basilar Artery Occlusion, Large Ischemic Core, Large Core Infarct, Endovascular Treatments
The First Affiliated Hospital of Hainan Medical University
Not applicable
372
Hefei, Haikou
2025-08-01
Not yet open
Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery
NCT07086287After Cardiac Surgery, Diuretic Resistance
The First Affiliated Hospital of Anhui Medical University
Not applicable
120
Hefei
2025-08-01
Recruiting
Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window
NCT06843356Acute Mild Ischemic Stroke, Basilar Artery Occlusion, Rescue Endovascular Treatment, Extended Time Window
First Affiliated Hospital of Wannan Medical College
Not applicable
159
Hefei, Wuhu
2025-08-01
Not yet open
Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
NCT07034118Esophageal Carcinoma
Anhui Provincial Hospital
Phase 1
23
Hefei
2025-08-01
Not yet open
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
NCT07047443Breast Cancer
Anhui Provincial Cancer Hospital
Phase 2
18
Hefei
2025-08-01
Not yet open
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739Primary Immune Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
320
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-08
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
NCT07128914Solid Tumor Malignancies
GeneSail Biotech (Shanghai) Co., Ltd.
Phase 1
32
Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai
2025-07-31
Recruiting
Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease
NCT07208344Alzheimer Disease (AD)
Anhui Provincial Hospital
Phase EARLY_PHASE1
30
Hefei
2025-07-31
Recruiting
Efficacy and Neural Mechanisms of Transcranial Direct Current Stimulation Targeting the Supplementary Motor Area for the Treatment of Subacute Post-stroke Aphasia
NCT07700537Post-stroke Aphasia
The First Affiliated Hospital of Anhui Medical University
Not applicable
40
Hefei
2025-07-30
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
416
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen
2025-07-25
Recruiting
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
NCT07213765Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
Phase 4
188
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease
NCT07174076Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
Phase 4
300
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Recruiting
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
NCT07232459Amyloid, Cardiac Amyloidosis, Amyloidosis, Healthy Subjects
Tianjin Medical University
Observational
25
Hefei, Qingdao, Tianjin
2025-07-21
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
Recruiting
CAR-T Cells Therapy for Patients With Autoimmune Diseases
NCT07052565Autoimmune Diseases
Anhui Provincial Hospital
Not applicable
18
Hefei
2025-07-20
Recruiting
A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)
NCT07672756Phenylketonuria (PKU)
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
48
Hefei
2025-07-20
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
Recruiting
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07292714Chronic Obstructive Pulmonary Disease COPD
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
360
Chizhou, Hefei, Lanzhou, Huizhou, Jiangmen, Qingyuan, Zunyi, Langfang
2025-07-15
Recruiting
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
NCT06898983Cancer Treatment-induced Thrombocytopenia (CTIT)
Anhui Provincial Hospital
Phase 2
97
Hefei
2025-07-14
Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
NCT07047456Acute Graft Versus Host Disease
Anhui Provincial Hospital
Phase 3
134
Hefei
2025-07-11
Recruiting
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
246
Bengbu, Hefei, Beijing, Fuzhou, Lanzhou, Jiangmen, Nanning, Guiyang
2025-07-07
Active, closed
An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer
NCT07096583Ovary Cancer
Anhui Provincial Cancer Hospital
Phase 1/2
20
Hefei
2025-07-07
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Recruiting
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
NCT06358209Central Nervous System Infections
RenJi Hospital
Not applicable
310
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin
2025-07-01
Recruiting
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
NCT07188103Esophageal Squamous Cell Carcinoma
Anhui Provincial Hospital
Phase 2
37
Hefei
2025-07-01
Active, closed
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
NCT07187505Acute Promyelocytic Leukemia (APL)
Anhui Medical University
Not applicable
28
Hefei
2025-07-01
Not yet open
Patient Journey in Advanced Gynecologic Cancers
NCT07015593Genital Neoplasms, Female, Uterine Cervical Neoplasms, Endometrial Carcinoma
Tongji Hospital
Observational
780
Hefei, Guangzhou, Wuhan, Chongqing
2025-07-01
By invitation
A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque
NCT07050134Hypertriglyceridemia, Carotid Atherosclerotic Plaques
Junbo Ge
Not applicable
40
Hefei, Suzhou, Shanghai
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Recruiting
A Phase I Study of SNH-119014 in Healthy Volunteers
NCT07087262Hemoglobinopathy
ScinnoHub Pharmaceutical Co., Ltd.
Phase 1
96
Hefei
2025-06-27
Recruiting
Evidence-based Practice in the Management of Gastric Tube Placement in Children
NCT07038538Hospitalized Children, Nursing, Enteral Nutrition Therapy
Children's Hospital of Fudan University
Not applicable
2,750
Shanghai, Beijing, Chongqing, Gansu, Guangdong, Hefei, Henan, Hunan
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Amgen
Phase 3
5,056
Hefei, Beijing, Guangzhou, Haikou, Qinhuangdao, Shijiazhuang, Harbin, Kaifeng
2025-06-25
Recruiting
Stellate Ganglion Morphine Infiltration on Myocardial I/R Injury
NCT07023679Acute Myocardial Infarction (AMI)
The Second Hospital of Anhui Medical University
Not applicable
2,588
Hefei
2025-06-24
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
NCT07085559Multiple Myeloma (MM), Plasma Cell Leukemia (PCL), AL Amyloidosis (AL)
Anhui Provincial Hospital
Phase EARLY_PHASE1
36
Hefei
2025-06-23
Recruiting
Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
NCT06926140Lung Cancers
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
240
Hefei, Beijing, Changsha
2025-06-21
Recruiting
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
NCT07125391Ovarian Cancer
Bai-Rong Xia
Phase 2
136
Hefei
2025-06-20
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy
NCT07030881Asthma, COPD
First Affiliated Hospital of Ningbo University
Not applicable
380
Hefei, Harbin, Ningbo, Ninghai, Taizhou
2025-06-17
Recruiting
Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
NCT06707194Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)
Nanfang Hospital, Southern Medical University
Phase 4
340
Hefei, Chongqing, Guangzhou, Hohhot, Ganzhou
2025-06-14
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd
Phase 2
141
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning
2025-06-13
Recruiting
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
NCT06892145Systemic Lupus Erythematosus (SLE), Refractory
Chongqing Precision Biotech Co., Ltd
Phase 1
12
Hefei, Hangzhou
2025-06-12
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT06783647Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984Agitation, Alzheimer Disease
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Recruiting
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
NCT06978920Parkinson Disease
Nuwacell Biotechnologies Co., Ltd.
Phase 1
48
Hefei
2025-06-06
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT06891833HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Recruiting
Standardized Implementation and Quality Assessment System for Confocal Enteroscopy
NCT07363291Confocal Enteroscopy, Quality Assessment System, Standardized Implementation
Shanghai Jiao Tong University School of Medicine
Observational
600
Hefei, Ningbo, Kashgar, Shanghai
2025-06-01
Recruiting
Artificial Intelligence for Pathology Diagnosis and Prognosis Prediction of Lung Nodule Using Smartphone Photos
NCT07098884Artificial Intelligence, Lung Nodule
Anhui Provincial Hospital
Observational
600
Hefei, Suzhou, Ningbo
2025-06-01
Recruiting
The Effects of Daytime, Nighttime, and Combined Heat Exposure on Human Health
NCT07501923Metabolism Changes, Psychology Functional Behavior, Cardiovascular System, Respiratory System
Jian Cheng
Not applicable
35
Hefei
2025-06-01
Active, closed
Transcranial Direct Current Stimulation for Cancer-related Cognitive Impairment in Breast Cancer Survivors
NCT07083518Transcranial Direct Current Stimulation (tDCS), Breast Cancer Survivor, Cognitive Impairment
Anhui Medical University
Not applicable
60
Hefei
2025-05-29
Active, closed
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Recruiting
Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
NCT06947135Acute Myocardial Infarction
The Second Hospital of Anhui Medical University
Not applicable
166
Hefei, Changsha
2025-05-29
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07002112Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
500
Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai
2025-05-22
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
NCT06934408Obesity, Overweight
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
92
Hefei
2025-05-08
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
BioNTech SE
Phase 1/2
594
Hefei, Beijing, Fuzhou, Nanning, Weihui, Zhengzhou, Jingzhou, Xiangyang
2025-05-02
Recruiting
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-05-01
Recruiting
Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease
NCT07118956Parkinson Disease, Apathy, Non-motor Symptoms, Vagus Nerve Stimulation
Anhui Medical University
Not applicable
60
Hefei
2025-05-01
Not yet open
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
NCT06958861Acute Exacerbations of Bronchiectasis
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2
180
Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang
2025-05
Not yet open
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
NCT06973343Colorectal Cancer Metastatic
Anhui Provincial Cancer Hospital
Phase 2
20
Hefei
2025-05
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920Primary Immune Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
199
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-04-30
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310Idiopathic Short Stature
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Recruiting
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
144
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou
2025-04-18
Recruiting
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NCT06961669Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital
Not applicable
18
Hefei
2025-04-16
Recruiting
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics
Observational
83
Hefei, Hangzhou, Wenzhou, Beijing, Shanghai
2025-04-02
Recruiting
Child-Parent Familial Hypercholesterolemia Screening
NCT04529967Familial Hypercholesterolemia
Children's Hospital of Fudan University
Observational
15,000
Hefei, Qidong, Shanghai, Taiyuan, Chongqing, Ürümqi
2025-04-01
Rows per page Showing 301–400 of 875
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hefei?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 875 of those studies with a site in Hefei.

How many clinical trials are recruiting in Hefei?

512 of the 875 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 137 have not yet opened recruitment, 211 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.